WO2002036148A3 - Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death - Google Patents
Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death Download PDFInfo
- Publication number
- WO2002036148A3 WO2002036148A3 PCT/EP2001/012440 EP0112440W WO0236148A3 WO 2002036148 A3 WO2002036148 A3 WO 2002036148A3 EP 0112440 W EP0112440 W EP 0112440W WO 0236148 A3 WO0236148 A3 WO 0236148A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- caspase
- dependent cell
- cell death
- rip
- death
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the use of physiologically occurring protein, in particular of death receptor ligands or RIP, to initiate the non-caspase-dependent cell death in immune system cells. The invention further relates to compounds, in particular also antibodies, which inhibit the initiation of the non-caspase-dependent cell death, with particular activity in inhibiting the signal transmission path by means of the protein RIP. The invention also relates to a method for identification of the above compounds.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002215036A AU2002215036A1 (en) | 2000-11-02 | 2001-10-26 | Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10054279.4 | 2000-11-02 | ||
DE10054279A DE10054279A1 (en) | 2000-11-02 | 2000-11-02 | Use of ligands from death receptors or RIP to trigger caspase-independent cell death and compounds to inhibit caspase-independent cell death |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002036148A2 WO2002036148A2 (en) | 2002-05-10 |
WO2002036148A3 true WO2002036148A3 (en) | 2003-05-30 |
Family
ID=7661879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/012440 WO2002036148A2 (en) | 2000-11-02 | 2001-10-26 | Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002215036A1 (en) |
DE (1) | DE10054279A1 (en) |
WO (1) | WO2002036148A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI637951B (en) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | Heterocyclic amides as kinase inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011793A1 (en) * | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
WO1997015586A1 (en) * | 1995-10-23 | 1997-05-01 | Tularik, Inc. | Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays |
US5674734A (en) * | 1995-05-18 | 1997-10-07 | President And Fellows Of Harvard College | Cell death protein |
FR2766713A1 (en) * | 1997-08-04 | 1999-02-05 | Bio Merieux | PROTEIN FACTOR ASSOCIATED WITH A NEURO-DEGENERATIVE AND / OR AUTO-IMMUNE AND / OR INFLAMMATORY DISEASE |
US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
-
2000
- 2000-11-02 DE DE10054279A patent/DE10054279A1/en not_active Withdrawn
-
2001
- 2001-10-26 WO PCT/EP2001/012440 patent/WO2002036148A2/en active Application Filing
- 2001-10-26 AU AU2002215036A patent/AU2002215036A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011793A1 (en) * | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
US5674734A (en) * | 1995-05-18 | 1997-10-07 | President And Fellows Of Harvard College | Cell death protein |
US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
WO1997015586A1 (en) * | 1995-10-23 | 1997-05-01 | Tularik, Inc. | Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays |
FR2766713A1 (en) * | 1997-08-04 | 1999-02-05 | Bio Merieux | PROTEIN FACTOR ASSOCIATED WITH A NEURO-DEGENERATIVE AND / OR AUTO-IMMUNE AND / OR INFLAMMATORY DISEASE |
Non-Patent Citations (7)
Title |
---|
BANKI K ET AL: "Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 FEB 1999, vol. 162, no. 3, 1 February 1999 (1999-02-01), pages 1466 - 1479, XP002207346, ISSN: 0022-1767 * |
HOLLER N ET AL: "Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.", NATURE IMMUNOLOGY. UNITED STATES DEC 2000, vol. 1, no. 6, December 2000 (2000-12-01), pages 489 - 495, XP001095602, ISSN: 1529-2908 * |
JAYANTHI SUBRAMANIAM ET AL: "Dual mechanism of Fas-induced cell death in neuroglioma cells: A role for reactive oxygen species.", MOLECULAR BRAIN RESEARCH, vol. 72, no. 2, 1 October 1999 (1999-10-01), pages 158 - 165, XP002207344, ISSN: 0169-328X * |
KAWAHARA ATSUO ET AL: "Caspase-independent cell killing of Fas-associated protein with death domain.", JOURNAL OF CELL BIOLOGY, vol. 143, no. 5, 30 November 1998 (1998-11-30), pages 1353 - 1360, XP002207345, ISSN: 0021-9525 * |
LÜSCHEN S ET AL: "Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 AUG 2000, vol. 275, no. 32, 11 August 2000 (2000-08-11), pages 24670 - 24678, XP002207402, ISSN: 0021-9258 * |
VERCAMMEN DOMINIQUE ET AL: "Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 5, 5 September 1998 (1998-09-05), pages 919 - 930, XP002207342, ISSN: 0022-1007 * |
VERCAMMEN DOMINIQUE ET AL: "Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 9, 4 May 1998 (1998-05-04), pages 1477 - 1485, XP002207343, ISSN: 0022-1007 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002036148A2 (en) | 2002-05-10 |
DE10054279A1 (en) | 2002-05-16 |
AU2002215036A1 (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001098358A3 (en) | Compositions for identification and isolation of stem cells | |
WO2003062375A3 (en) | Stabilizing polypeptides which have been exposed to urea | |
WO1999020756A3 (en) | Human toll homologues | |
WO2003045427A3 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
ZA200109901B (en) | Method for down-regulating GDF-8 activity. | |
WO2002032375A8 (en) | Uses of monoclonal antibody 8h9 | |
WO2002057783A3 (en) | Method of screening for gpr40 ligands | |
WO2004048517A3 (en) | Method for reducing or preventing modification of a polypeptide in solution | |
ZA99493B (en) | Method for the isolation of nucleic acid. | |
HK1052702A1 (en) | Method for the preparation of 5-carboxyphthalide. | |
ZA200203320B (en) | Spiro(2H-1-benzopyran-2,4'-piperidine)derivatives as glycine transport inhibitors. | |
WO2000050607A3 (en) | Goodpasture antigen binding protein | |
WO2006091535A3 (en) | Novel egg receptors for sperm proteins | |
WO2001071942A3 (en) | Method and system for detecting signals with multiple antennas | |
WO2001009384A3 (en) | Serial analysis of genetic alterations | |
IT1293978B1 (en) | FERMENTATION TANK, PARTICULARLY FOR THE RED VINIFICATION. | |
WO2002036148A3 (en) | Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death | |
WO1998046632A3 (en) | Inhibitors for urokinase receptor | |
WO2002074904A3 (en) | Rearranged squamous cell carcinoma antigen genes ii | |
EP1400807A3 (en) | Use of novel stem cell markers for isolation of intestinal stem cells, and use of the intestinal stem cells thus obtained for the preparation of a therapeutical composition | |
AU7165891A (en) | Tumor-specific, cell surface-binding monoclonal antibodies | |
WO2002086505A3 (en) | Intracellular analysis | |
WO2001053339A3 (en) | Egg specific surface proteins | |
EP0112299A3 (en) | Method for superoxidic-dismutasis purification via chromatography by affinity | |
AU4605099A (en) | Method for detecting infection-phase-specific antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |